fluorouracil has been researched along with Neoplasms, Pleural in 40 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The CALGB performed a phase II multicenter study to evaluate the activity of oral capecitabine in patients with malignant mesothelioma (CALGB 39807)." | 9.11 | Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). ( Green, MR; Herndon, JE; Kindler, HL; Otterson, GA; Watson, D, 2004) |
| "The purpose of the present study is to evaluate what clinical factors affect the efficacy, time to treatment failure (TTF), and overall survival (OS) of oral capecitabine monotherapy in heavily pretreated patients with metastatic breast cancer (MBC)." | 7.75 | Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer. ( Hatake, K; Ito, Y; Iwase, T; Matsuura, M; Osako, T; Sugihara, T; Takahashi, S; Tokudome, N; Ushijima, M, 2009) |
| "The pharmacokinetic of 5-Fluorouracil and its permeation into malignant pleural effusion was investigated in 9 patients with breast carcinoma who received 600 mg/m2 5-Fluorouracil i." | 7.67 | [Pharmacokinetics of 5-fluorouracil and its permeation in pleural effusions in the therapy of metastatic breast cancer]. ( Wagner, T, 1984) |
| "Twenty consecutive patients with a confirmed diagnosis of diffuse malignant mesothelioma of the pleura or peritoneum, previously untreated with chemotherapy, were studied in a Phase II trial of single-agent 5-fluorouracil." | 7.67 | Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin. ( Blackshaw, AJ; Harvey, VJ; Ponder, BA; Slevin, ML; Wrigley, PF, 1984) |
| "Thirty consecutive patients with metastatic breast cancer previously untreated by chemotherapy were given high-dose cyclophosphamide (Cytoxan) and high-dose 5-fluorouracil (5-FU) as first-line therapy." | 7.67 | High-dose cyclophosphamide and high-dose 5-fluorouracil. A new first-line regimen for advanced breast cancer. ( Aguilera, J; Breau, JL; Israel, L, 1984) |
| " Pharmacokinetic analysis was performed on plasma samples collected at the first cycle of treatment." | 5.35 | A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. ( Antonuzzo, A; Bocci, G; Bursi, S; Chiara, S; Del Tacca, M; Di Paolo, A; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Pfanner, E; Vasile, E, 2009) |
| "In evaluating response by sites of metastases, lymph nodes (30%), lung nodules (22%), and subcutaneous deposits (2/3) had the highest incidence of C." | 5.25 | An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer. ( Catalano, RB; Creech, RH; Engstrom, PF; Mastrangelo, MJ, 1975) |
| "The CALGB performed a phase II multicenter study to evaluate the activity of oral capecitabine in patients with malignant mesothelioma (CALGB 39807)." | 5.11 | Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). ( Green, MR; Herndon, JE; Kindler, HL; Otterson, GA; Watson, D, 2004) |
| "The purpose of the present study is to evaluate what clinical factors affect the efficacy, time to treatment failure (TTF), and overall survival (OS) of oral capecitabine monotherapy in heavily pretreated patients with metastatic breast cancer (MBC)." | 3.75 | Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer. ( Hatake, K; Ito, Y; Iwase, T; Matsuura, M; Osako, T; Sugihara, T; Takahashi, S; Tokudome, N; Ushijima, M, 2009) |
| "The pharmacokinetic of 5-Fluorouracil and its permeation into malignant pleural effusion was investigated in 9 patients with breast carcinoma who received 600 mg/m2 5-Fluorouracil i." | 3.67 | [Pharmacokinetics of 5-fluorouracil and its permeation in pleural effusions in the therapy of metastatic breast cancer]. ( Wagner, T, 1984) |
| "Twenty consecutive patients with a confirmed diagnosis of diffuse malignant mesothelioma of the pleura or peritoneum, previously untreated with chemotherapy, were studied in a Phase II trial of single-agent 5-fluorouracil." | 3.67 | Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin. ( Blackshaw, AJ; Harvey, VJ; Ponder, BA; Slevin, ML; Wrigley, PF, 1984) |
| "Thirty consecutive patients with metastatic breast cancer previously untreated by chemotherapy were given high-dose cyclophosphamide (Cytoxan) and high-dose 5-fluorouracil (5-FU) as first-line therapy." | 3.67 | High-dose cyclophosphamide and high-dose 5-fluorouracil. A new first-line regimen for advanced breast cancer. ( Aguilera, J; Breau, JL; Israel, L, 1984) |
| "Malignant pleural mesothelioma is associated with a poor prognosis because of its resistance to treatment." | 2.69 | Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura. ( Astoul, P; Boutin, C; Kasseyet, S, 1999) |
| " Pharmacokinetic analysis was performed on plasma samples collected at the first cycle of treatment." | 1.35 | A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. ( Antonuzzo, A; Bocci, G; Bursi, S; Chiara, S; Del Tacca, M; Di Paolo, A; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Pfanner, E; Vasile, E, 2009) |
| "This suggested that the therapy for a breast cancer patient with distant metastasis must be considered according to the region of recurrence." | 1.30 | [A case of hepatic arterial infusion chemotherapy for multiple liver metastasis from breast cancer]. ( Ayabe, H; Hara, S; Hashizume, S; Itoyanagi, N; Oka, T; Shinguu, H; Tagawa, Y; Tooyama, H; Tou, K; Tsuji, H; Yamamoto, S; Yamazumi, K, 1997) |
| " 5-FU was administered intracavitary in all patients combined with systemic chemotherapy." | 1.28 | Intracavitary 5-fluoro-uracil (5-FU) in combination with systemic chemotherapy. ( Boaziz, C; Breau, JL; Delanian, S; Israel, L; Morere, JF, 1989) |
| "Seventeen patients with primary liver cancer were also treated with adriamycin." | 1.26 | Adriamycin in the treatment of cancer. ( Falkson, G; Falkson, HC; van der Merwe, AM; van Dyk, JJ, 1976) |
| "In evaluating response by sites of metastases, lymph nodes (30%), lung nodules (22%), and subcutaneous deposits (2/3) had the highest incidence of C." | 1.25 | An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer. ( Catalano, RB; Creech, RH; Engstrom, PF; Mastrangelo, MJ, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 25 (62.50) | 18.7374 |
| 1990's | 7 (17.50) | 18.2507 |
| 2000's | 7 (17.50) | 29.6817 |
| 2010's | 1 (2.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atanaskova Mesinkovska, N | 1 |
| Conic, RZ | 1 |
| Kiracofe, EA | 1 |
| Vidimos, AT | 1 |
| Osako, T | 1 |
| Ito, Y | 2 |
| Ushijima, M | 1 |
| Takahashi, S | 2 |
| Tokudome, N | 2 |
| Sugihara, T | 2 |
| Iwase, T | 2 |
| Matsuura, M | 1 |
| Hatake, K | 2 |
| Osaki, Y | 1 |
| Fornaro, L | 1 |
| Masi, G | 1 |
| Bursi, S | 1 |
| Loupakis, F | 1 |
| Vasile, E | 1 |
| Antonuzzo, A | 1 |
| Chiara, S | 1 |
| Pfanner, E | 1 |
| Di Paolo, A | 1 |
| Bocci, G | 1 |
| Del Tacca, M | 1 |
| Falcone, A | 1 |
| KOOP, CE | 1 |
| Otterson, GA | 1 |
| Herndon, JE | 1 |
| Watson, D | 1 |
| Green, MR | 1 |
| Kindler, HL | 1 |
| Suzuki, M | 1 |
| Dang, A | 1 |
| Mansfield, P | 1 |
| Ilsin, B | 1 |
| Hightower, C | 1 |
| Aravindan, N | 1 |
| Rice, D | 1 |
| Riedel, B | 1 |
| Brocard, H | 2 |
| Akoun, G | 2 |
| Turpin, G | 1 |
| Gendre, JP | 1 |
| Wagner, T | 1 |
| Harvey, VJ | 1 |
| Slevin, ML | 1 |
| Ponder, BA | 1 |
| Blackshaw, AJ | 1 |
| Wrigley, PF | 1 |
| Israel, L | 2 |
| Breau, JL | 2 |
| Aguilera, J | 1 |
| Moriyama, A | 1 |
| Murata, I | 1 |
| Kuroda, T | 1 |
| Yoshikawa, I | 1 |
| Tabaru, A | 1 |
| Ogami, Y | 1 |
| Otsuki, M | 1 |
| Oura, S | 1 |
| Sakurai, T | 1 |
| Yoshimura, G | 1 |
| Tamaki, T | 1 |
| Umemura, T | 1 |
| Hara, S | 1 |
| Hashizume, S | 1 |
| Itoyanagi, N | 1 |
| Ayabe, H | 1 |
| Tagawa, Y | 1 |
| Tsuji, H | 1 |
| Oka, T | 1 |
| Yamamoto, S | 1 |
| Shinguu, H | 1 |
| Tou, K | 1 |
| Tooyama, H | 1 |
| Yamazumi, K | 1 |
| Kanematsu, A | 1 |
| Inoue, T | 1 |
| Nakano, T | 1 |
| Segawa, T | 1 |
| Kakehi, Y | 1 |
| Hiura, M | 1 |
| Hashimura, T | 1 |
| Chauffert, B | 1 |
| Bonnotte, B | 1 |
| Chvetzoff, G | 1 |
| Flesch, M | 1 |
| Kasseyet, S | 1 |
| Astoul, P | 1 |
| Boutin, C | 1 |
| Omasa, M | 1 |
| Hirata, T | 1 |
| Shoji, T | 1 |
| Bando, T | 1 |
| Hasegawa, S | 1 |
| Inui, K | 1 |
| Wada, H | 1 |
| Legha, SS | 1 |
| Muggia, FM | 1 |
| Creech, RH | 1 |
| Catalano, RB | 1 |
| Mastrangelo, MJ | 1 |
| Engstrom, PF | 1 |
| van Dyk, JJ | 1 |
| van der Merwe, AM | 1 |
| Falkson, HC | 1 |
| Falkson, G | 1 |
| Kucuksu, N | 1 |
| Thomas, W | 1 |
| Ezdinli, EZ | 1 |
| Umsawasdi, T | 1 |
| Dhingra, HM | 1 |
| Charnsangavej, C | 1 |
| Luna, MA | 1 |
| Morere, JF | 1 |
| Delanian, S | 1 |
| Boaziz, C | 1 |
| Markman, M | 1 |
| Lebeau, B | 1 |
| Brechot, JM | 1 |
| Ameille, J | 1 |
| de Fenoyl, O | 1 |
| Rochemaure, J | 1 |
| Sievers, DB | 1 |
| Donovan, AJ | 1 |
| Asakura, H | 1 |
| Gerner, RE | 1 |
| Moore, GE | 1 |
| Umhauer, I | 1 |
| Dymarskiĭ, LIu | 1 |
| Chernomordikova, MF | 1 |
| Perlia, CP | 1 |
| Molina, C | 1 |
| Cheminat, JC | 1 |
| Passemard, N | 1 |
| Adam, J | 1 |
| Migueres, J | 1 |
| Jover, A | 1 |
| Levy, A | 1 |
| Wilson, RE | 1 |
| Piro, AJ | 1 |
| Aliapoulios, MA | 1 |
| Moore, FD | 1 |
| Manzur, R | 1 |
| Oliva Otero, G | 1 |
| Tano Assini, MT | 1 |
| Genevrier, R | 1 |
| Gouletquer, J | 1 |
| Martz, G | 1 |
| Danczkay, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase Ⅱ Clinical Study of RALOX or CAPOX Combined With Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer[NCT03813641] | Phase 2 | 100 participants (Anticipated) | Interventional | 2019-01-28 | Recruiting | ||
| Capecitabine (Xeloda) in Malignant Mesothelioma: A Phase II Study[NCT00004183] | Phase 2 | 27 participants (Actual) | Interventional | 2000-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for fluorouracil and Neoplasms, Pleural
| Article | Year |
|---|---|
Therapeutic approaches in malignant mesothelioma.
Topics: Alkylating Agents; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Therapy, | 1977 |
Cytotoxic intracavitary chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Catheterization; Cisplatin; Clinical Tr | 1986 |
4 trials available for fluorouracil and Neoplasms, Pleural
| Article | Year |
|---|---|
Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; | 2004 |
[Combination therapy of daily intramuscular injection of interferon-alpha and oral administration of fluorouracil for advanced renal cell carcinoma].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; | 1998 |
Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asbestos; Cisplatin; Combined Modality | 1999 |
Cytotoxic intracavitary chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Catheterization; Cisplatin; Clinical Tr | 1986 |
35 other studies available for fluorouracil and Neoplasms, Pleural
| Article | Year |
|---|---|
Treatment of invasive squamous cell carcinomas in an open Clagett window.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Debride | 2015 |
Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; C | 2009 |
Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Bone Neoplasms; Bre | 2009 |
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptotheci | 2009 |
CURRENT MANAGEMENT OF NEPHROBLASTOMA AND NEUROBLASTOMA.
Topics: Antineoplastic Agents; Child; Dactinomycin; Fluorouracil; Infant; Infant, Newborn; Kidney Neoplasms; | 1964 |
[A patient with advanced breast cancer refractory to chemotherapy accompanied by carcinomatous pleurisy and multiple bone metastasis that responded to combination therapy with high-dose toremifene and docetaxel].
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplas | 2007 |
Intraoperative hyperthermic intrathoracic chemotherapy for pleural extension of pseudomyxoma peritonei.
Topics: Adult; Anesthesia, General; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemothera | 2007 |
[Attack treatment of broncho-pleuro-pulmonary cancer by polychemotherapy under the protection of phytohemagglutinin].
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Azirines; Betametha | 1967 |
[Pharmacokinetics of 5-fluorouracil and its permeation in pleural effusions in the therapy of metastatic breast cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Breast Neoplasms; Chr | 1984 |
Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin.
Topics: Adult; Aged; Doxorubicin; Drug Evaluation; Female; Fluorouracil; Humans; Male; Mesothelioma; Middle | 1984 |
High-dose cyclophosphamide and high-dose 5-fluorouracil. A new first-line regimen for advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1984 |
Pericardiac metastasis from advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Fluorouracil; Heart Neoplasms; Human | 1995 |
[A case of recurrent breast carcinoma with metastatic foci in the lung and pleura treated successfully with biochemical modulation of 5-fluorouracil by low-dose cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Administrati | 1996 |
[A case of hepatic arterial infusion chemotherapy for multiple liver metastasis from breast cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Co | 1997 |
[The major response of metastatic kidney cancer to the combination of oxaliplatin, 5-fluorouracil and folinic acid (FOX-FOL)].
Topics: Adenocarcinoma, Clear Cell; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antin | 1998 |
A case of repetitive intrapleural cancer chemotherapy using INFUSE-A-PORT for malignant mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Chemotherapy, Cancer, Regiona | 2001 |
An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; | 1975 |
Adriamycin in the treatment of cancer.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cyclophosphamide; Doxorubicin; Drug Therapy, Combi | 1976 |
Chemotherapy of malignant diffuse mesothelioma.
Topics: Aged; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; | 1976 |
A case report of malignant pleural mesothelioma with long-term disease control after chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; | 1991 |
Intracavitary 5-fluoro-uracil (5-FU) in combination with systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Combined Modalit | 1989 |
[Chemotherapy of bronchopulmonary and pleural adenocarcinoma. Apropos of 31 cases].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophospha | 1985 |
Palliative treatment of mammary cancer. Response of soft tissue, pleural and pulmonary disease.
Topics: Adrenalectomy; Adult; Age Factors; Aged; Breast Neoplasms; Castration; Cyclophosphamide; Dexamethaso | 1973 |
[Treatment of malignant pleural effusions by intracavitary injection of mixture of 5FU, cyclophosphamide, mitomycin C, bleomycin and thioinosine].
Topics: Adult; Aged; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Cyclophosphamid | 1973 |
Chemotherapy of malignant mesothelioma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Fluorouracil; Glucosamine; Humans; Male; Mesothelioma; M | 1974 |
[Results of polycytostatic therapy in tumorous pleural effusion (author's transl)].
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Me | 1974 |
[Features of regressive changes during chemotherapy of breast cancer metastases to the lungs].
Topics: Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Lung Neoplasms; Middle Aged; Neopl | 1972 |
The problems of drug treatment of breast cancer.
Topics: Age Factors; Alkylating Agents; Androgens; Bone Neoplasms; Breast Neoplasms; Corticosterone; Drug Co | 1973 |
[Our experiences with polychemotherapy of malignant endothoracic tumors (103 cases)].
Topics: Adenocarcinoma; Adult; Androgens; Antineoplastic Agents; Azirines; Bronchial Neoplasms; Carcinoma; C | 1968 |
[3 years of polychemotherapy of pleuro-pulmonary cancer. Apropos of 95 cases].
Topics: Androgens; Antibiotics, Antineoplastic; Antineoplastic Agents; Ascorbic Acid; Azirines; Bronchial Ne | 1968 |
Treatment of metastatic breast cancer with a combination of adrenalectomy and 5-fluorouracil. Progress report.
Topics: Adrenalectomy; Aged; Bone Neoplasms; Breast Neoplasms; Female; Fluorouracil; Follow-Up Studies; Huma | 1971 |
[Effect of antineoplastic drug therapy in the management of tumor cells of pleural and ascitic effusion].
Topics: Ascites; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Mesothelioma; Mustard Com | 1970 |
[The results of attack polychemotherapy in broncho-pleuro-pulmonary cancer. Phytohemagglutinin in the prevention and treatment of hematologic complications of antimitotics].
Topics: Anemia, Aplastic; Antibiotics, Antineoplastic; Antineoplastic Agents; Azirines; Bronchial Neoplasms; | 1968 |
[Trial polychemotherapy of inoperable cancer (apropos of 71 cases)].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Azirines; Bronchial Neoplasms; Carcinoma, Squamo | 1968 |
[Cytostatic therapy of lung and pleural neoplasms].
Topics: Cyclophosphamide; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pleu | 1965 |